HOME >> MEDICINE >> NEWS
Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent

PARIS (May 22, 2002) -- Clinical investigators today reported preliminary findings at The Paris Course on Revascularization (PCR) documenting the excellent results of the CYPHER Sirolimus-eluting Stent in the first 400 patients enrolled in the landmark SIRIUS study. SIRIUS is a large-scale, randomized, double-blind, controlled clinical trial involving 53 U.S. treatment centers and 1,101 patients. The study was sponsored by Cordis Corporation, a Johnson & Johnson company.

Co-Principal Investigators, Martin B. Leon, M.D., and Jeffrey W. Moses, M.D., Interventional Cardiology, Cardiovascular Research Foundation, Lenox Hill Hospital, New York, NY, presented 8-month angiographic and 9-month clinical data. Peter J. Fitzgerald, M.D., Ph.D., Associate Professor of Medicine and Director of the CV Core Analysis Laboratory, Stanford University Medical Center, Palo Alto, CA, presented 8-month intravenous ultrasound (IVUS) data on 96 patients.

The SIRIUS preliminary data are the most recent in a series of study findings evaluating the efficacy and safety of the CYPHER Sirolimus-eluting Stent in reducing reblockage of de novo coronary artery lesions.

"We are extremely impressed by the consistency in findings between the preliminary SIRIUS data and the results of the large-scale RAVEL* study in Europe and Latin America," said Dr. Leon.

Eight-month angiographic follow-up showed virtually no in-stent late lumen loss (0.14 mm) in patients treated with the CYPHER Stent, mirroring the 6-month findings of the RAVEL study and the 2-year findings of the First-in-Man study. The 2% rate of angiographic in-stent restenosis representing a 94% reduction versus the control arm (bare metal stent) supports the findings of earlier studies.

"The major reductions in angiographic in-stent restenosis and late lumen loss associated with the CYPHER Sirolimus-eluting Stent are proving to be remarkably similar from study to study," said Dr. Leon. "S
'"/>

Contact: Martin E. Schildhouse
mschildh@crdus.jnj.com
305-606-3577
Cordis Corporation
22-May-2002


Page: 1 2 3

Related medicine news :

1. Preliminary results are promising in Alzheimers gene therapy trial
2. Preliminary report suggests combination therapy may help treat SARS
3. Preliminary study finds stem cells in blood restore damaged heart muscle
4. Preliminary study suggests endomitriosis could contribute to infertility
5. Preliminary study shows high-dose coenzyme Q10 slows functional decline in Parkinsons patients
6. Preliminary Study Proves Centuries Of Herbalists Right About Echinacea
7. ACTG 315 Preliminary Results: Drug Cocktail Restores Partial Immune Function
8. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
9. UMaine study looks at infants and chronic nighttime crying
10. Chronic pain treatments more effective when taken together, new study shows
11. UNC study: Most N.C. family practitioners engage in unrecognized community service

Post Your Comments:
(Date:6/18/2013)... Seven-year-old Riley Salz of Encino, California, is ... 40 hours a week of applied behavior analysis (ABA) ... for Autism and Related Disorders (CARD). Riley has been ... experienced remarkable progress, including learning to speak, starting conversations, ... journey through autism is now featured in CARD’s “Mission ...
(Date:6/18/2013)... at Case Western Reserve University,s College of Arts ... made available avatarsvirtual patientsto train speech-language pathologists. ... to evaluate speech-language disorders to practice using an ... because a diagnosis doesn,t have to be made ... studying to become speech-language pathologists have previously relied ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 The Elizabeth ... of State and the U.S. President’s Emergency Plan for ... and celebrate significant new milestones in the global effort ... John Kerry announced that as of June 2013, one ... PEPFAR support. Since PEPFAR’s inception in 2003, EGPAF ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 A new ... storm. The burgeoning aquaculture industry is redefining the way ... of the most acclaimed personal culinary chefs on the ... on benefits of sustainable seafood and the promising industry ... abundance these days. Many consumers strive to fully partake ...
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 New York ... Center to its “Best Doctors” list, up from 129 ... York City. The new issue also lists 52 additional doctors ... continues on a strategic growth trajectory. The “Best Doctors” issue, ... in the June 24 print issue and is available online ...
Breaking Medicine News(10 mins):Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:New $119 Million Industry Swimming Up the East Coast 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3
(Date:6/17/2013)... June 17, 2013 Vanda Pharmaceuticals Inc. ... data today at ENDO 2013, the Endocrine Society,s ... can entrain (synchronize) both melatonin and cortisol rhythms. ... the master body clock and address the circadian ... The SET (Safety and Efficacy of Tasimelteon) and ...
(Date:6/17/2013)... DNAtrix Inc., experts in oncolytic virus development, ... on the company,s lead product, DNX-2401, at the Replicating ... Canada on June 18, 2013. ... leader in the field of oncolytic virus therapy, will ... I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY ...
(Date:6/17/2013)... , June 17, 2013 BioMed Realty Trust, Inc. ... of directors has declared a second quarter 2013 dividend of ... to an annualized dividend of $0.94 per common share. ... 15, 2013 to stockholders of record at the close of ... Realty Trust BioMed Realty delivers optimal real estate ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
Cached News: